Challenges obtaining a biowaiver for topical veterinary dosage forms.

Area of Science:

• Veterinary Dermatology
• Pharmaceutical Sciences
• Drug Bioequivalence

Background:

• Topical drug development for veterinary species shares challenges with human applications.
• Veterinary skin exhibits anatomical and biochemical differences from human skin, complicating bioequivalence (BE) assessments.
• Locally acting drugs pose particular difficulties in establishing BE for veterinary topicals.

Purpose of the Study:

• To identify and address challenges in determining bioequivalence (BE) for veterinary topical drugs.
• To critically evaluate current technological advancements that can serve as surrogates for clinical trials in veterinary BE studies.

Main Methods:

• Review of existing literature on veterinary topical drug bioequivalence.
• Analysis of anatomical and biochemical skin differences between human and domestic animal species.
• Examination of in vitro and in silico technologies for assessing topical drug performance.

Main Results:

• Veterinary skin's complexity necessitates species-specific bioequivalence assessment strategies.
• Technological advancements offer potential alternatives to traditional in vivo bioequivalence testing.
• Standardized methodologies are needed for evaluating veterinary topical drug formulations.

Conclusions:

• Overcoming challenges in veterinary topical drug bioequivalence requires tailored approaches.
• Emerging technologies show promise for replacing or supplementing clinical trials.
• Further research is needed to validate surrogate methods for veterinary drug approval.